Status:
UNKNOWN
Pulmonary Microbiota and ARDS Mortality
Lead Sponsor:
University of Bordeaux
Conditions:
Acute Respiratory Distress Syndrome
Eligibility:
All Genders
18+ years
Brief Summary
Acute respiratory distress syndrome (ARDS) is due to diffuse and severe lung inflammation. Despite intensive research, few therapeutics have emerged and treatment is still mostly symptomatic. As lung ...
Detailed Description
ARDS is caused by diffuse intense lun inflammation. Its mortality rate is still about 40%. Despite decades of research, few therapeutics have emerged. Treatment is based on the treatment of ARDS cause...
Eligibility Criteria
Inclusion
- Patient above 18 year-old admitted to intensive care unit
- ARDS according to Berlin criteria
- Needing oro-tracheal intubation for mechanical ventilation
- Within the first 48 hours of ARDS evolution
Exclusion
- Guardianship or curatorship
- Prisoners
- No health insurance
- No legal representative
Key Trial Info
Start Date :
October 31 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 1 2020
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT04133558
Start Date
October 31 2019
End Date
November 1 2020
Last Update
November 1 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical intensive care unit, Pellegrin hospital
Bordeaux, Nouvelle-Aquitaine, France, 33000